Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 131, Issue 4
January 25 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
Peripheral T-cell lymphoma: novel backbone
Clinical Trials & Observations
Julie M. Vose
View Articletitled, Peripheral T-cell lymphoma: novel backbone
Hematopoiesis and Stem Cells
TP53 mutations: the dawn of Shwachman clones
Jean Donadieu,François Delhommeau
View Articletitled, <em>TP53</em> mutations: the dawn of Shwachman clones

HOW I TREAT

How I treat CLL patients with ibrutinib
Clinical Trials & Observations
Jennifer R. Brown
View Articletitled, How I treat CLL patients with ibrutinib

CLINICAL TRIALS AND OBSERVATIONS

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Clinical Trials & Observations
Eytan M. Stein,Roland B. Walter,Harry P. Erba,Amir T. Fathi,Anjali S. Advani,Jeffrey E. Lancet,Farhad Ravandi,Tibor Kovacsovics,Daniel J. DeAngelo,Dale Bixby,Stefan Faderl,Anand P. Jillella,Phoenix A. Ho,Megan M. O’Meara,Baiteng Zhao,Charles Biddle-Snead,Anthony S. Stein
View Articletitled, A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Supplemental data
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Clinical Trials & Observations
Jennifer E. Amengual,Renee Lichtenstein,Jennifer Lue,Ahmed Sawas,Changchun Deng,Emily Lichtenstein,Karen Khan,Laine Atkins,Aishling Rada,Hye A. Kim,Codruta Chiuzan,Matko Kalac,Enrica Marchi,Lorenzo Falchi,Mark A. Francescone,Lawrence Schwartz,Serge Cremers,Owen A. O’Connor
View Articletitled, A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Somatic mutations and clonal hematopoiesis in congenital neutropenia
Jun Xia,Christopher A. Miller,Jack Baty,Amrita Ramesh,Matthew R. M. Jotte,Robert S. Fulton,Tiphanie P. Vogel,Megan A. Cooper,Kelly J. Walkovich,Vahagn Makaryan,Audrey A. Bolyard,Mary C. Dinauer,David B. Wilson,Adrianna Vlachos,Kasiani C. Myers,Robert J. Rothbaum,Alison A. Bertuch,David C. Dale,Akiko Shimamura,Laurence A. Boxer,Daniel C. Link
View Articletitled, Somatic mutations and clonal hematopoiesis in congenital neutropenia
Supplemental data

LYMPHOID NEOPLASIA

Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network
Clinical Trials & Observations Brief Report
Sietse M. Aukema,Eva Hoster,Andreas Rosenwald,Danielle Canoni,Marie-Hélène Delfau-Larue,Grzegorz Rymkiewicz,Christoph Thorns,Sylvia Hartmann,Hanneke Kluin-Nelemans,Olivier Hermine,Martin Dreyling,Wolfram Klapper
View Articletitled, Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network
Supplemental data
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL
Brief Report
Sandrine Degryse,Simon Bornschein,Charles E. de Bock,Emilie Leroy,Marlies Vanden Bempt,Sofie Demeyer,Kris Jacobs,Ellen Geerdens,Olga Gielen,Jean Soulier,Christine J. Harrison,Stefan N. Constantinescu,Jan Cools
View Articletitled, Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL
Supplemental data

MYELOID NEOPLASIA

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
Takeshi Yamaura,Toshiyuki Nakatani,Ken Uda,Hayato Ogura,Wigyon Shin,Naoya Kurokawa,Koichi Saito,Norie Fujikawa,Tomomi Date,Masaru Takasaki,Daisuke Terada,Atsushi Hirai,Akimi Akashi,Fangli Chen,Yoshiya Adachi,Yuichi Ishikawa,Fumihiko Hayakawa,Shinji Hagiwara,Tomoki Naoe,Hitoshi Kiyoi
View Articletitled, A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with <em>FLT3</em> mutations
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2
Mieke De Buck,Mieke Gouwy,Nele Berghmans,Ghislain Opdenakker,Paul Proost,Sofie Struyf,Jo Van Damme
View Articletitled, COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2

RED CELLS, IRON, AND ERYTHROPOIESIS

HRI coordinates translation by eIF2αP and mTORC1 to mitigate ineffective erythropoiesis in mice during iron deficiency
Shuping Zhang,Alejandra Macias-Garcia,Jason Velazquez,Elena Paltrinieri,Randal J. Kaufman,Jane-Jane Chen
View Articletitled, HRI coordinates translation by eIF2αP and mTORC1 to mitigate ineffective erythropoiesis in mice during iron deficiency
Supplemental data

LETTERS TO BLOOD

Single-board hematology fellowship track: a 10-year institutional experience
Rakhi P. Naik,Kristen Marrone,Samuel Merrill,Ross Donehower,Robert Brodsky
View Articletitled, Single-board hematology fellowship track: a 10-year institutional experience
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents
Maria Gavriatopoulou,Efstathios Kastritis,Ioannis Ntanasis-Stathopoulos,Despina Fotiou,Maria Roussou,Magdalini Migkou,Dimitrios C. Ziogas,Nikolaos Kanellias,Evangelos Terpos,Meletios Athanasios Dimopoulos
View Articletitled, The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
Clinical Trials & Observations
Rosemary E. Gale,Teodora Popa,Melissa Wright,Naeem Khan,Sylvie D. Freeman,Alan K. Burnett,Nigel H. Russell,Robert K. Hills,David C. Linch
View Articletitled, No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
Supplemental data

BLOOD WORK

A pernicious mean corpuscular volume
Alexa S. Green,Nicolas Chapuis
View Articletitled, A pernicious mean corpuscular volume
  • Cover Image

    Cover Image

    issue cover

    A blood smear (Wright-Giemsa stain) from an iron-deficient Hri−/− mouse treated daily with rapamycin for 12 days. The iron deficiency anemia is significantly improved with increased hemoglobin levels and red blood cell numbers as well as a reduction of reticulocyte percentage. However, reticulocytes (blue cells) still display visible globin inclusions (pink aggregates), demonstrating an essential role of heme-regulated eIF2αP in inhibiting globin translation. See the article by Zhang et al on page 450.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkBack Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads
Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia
Leukemic myeloblasts with erythrophagocytosis

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals